Zobrazení zdroje stránky Gisselburns7983

Conclusion TonguePART is a fast, reliable method of tracking articulatory movement of tongue parts for syllables such as /ɑr/. It is extensible to other sounds and phonetic contexts. By tracking tongue parts, clinical researchers can investigate lingual coordination. TonguePART is suitable for real-time data collection and biofeedback. Ultrasound biofeedback therapy users may make more progress using simplified biofeedback of tongue movement.Objective Graves disease (GD) has a well-known association with thymic hyperplasia, which is seen histo-logically in up to 38% of patients with GD. However, there have only been approximately 100 documented cases of Graves-associated massive thymic hyperplasia. Potential mechanisms of thymic pathology are reviewed. Methods A 24-year-old female presented to the emergency department with dyspnea, palpitations, tachycardia, anxiety, and weight loss. She was evaluated for hyperthyroidism using labs (thyroid-stimulating hormone, free thyroxine, thyroid-stimulating immunoglobulins) and imaging (radioactive iodine uptake [RAIU] scan), leading to treatment with radioiodine. A computed tomography angiogram of the chest was also performed to evaluate for pulmonary embolism given the patient's presenting symptoms. Results Our patient was found to have undetectable thyroid-stimulating hormone, elevated free thyroxine (2.9 ng/dL), and elevated thyroid-stimulating immunoglobulins (399%). Diagnosis of GD was confirmed on RAIU scan. The computed tomography chest angiogram demonstrated a significant anterior mediastinal mass (7.9 × 6.9 × 6.3 cm). Treatment with radioiodine led to reduction of the mass by 76% in volume. Conclusion While the patient's thyroid labs and RAIU scan were consistent with GD, the presence of massive thymic hyperplasia was atypical. However, the resolution of thymic hyperplasia after radioiodine therapy, without the use of thymectomy, was similar to other reported cases.Objective Multiple case reports have implicated the use of heparin for deep vein thrombosis (DVT) prophylaxis with bilateral adrenal hemorrhage. Only 1 previous report has described this with the low molecular weight product, dalteparin. We report a case following bilateral hip arthroplasties. Methods Clinical and laboratory data are presented. Results A 69-year-old woman underwent bilateral total hip arthroplasties with dalteparin 5,000 international units subcutaneously daily for 30 days postoperatively. The patient's past medical history was unremarkable. She was discharged 5 days post-surgery and required readmission 1 day later for epigastric pain, nausea, and vomiting. Her platelet count was 91 × 109/L (normal, 150 to 400 × 109/L). She was discharged after 4 days with pain resolution. She presented 4 weeks later with nausea and vomiting for several days. Serum sodium was 123 mmol/L (normal, 133 to 145 mmol/L), potassium was 6.0 mmol/L (normal, 3.7 to 5.3 mmol/L), total calcium was 3.37 mmol/L (normal, 2.25 to 2.80 mmol/L), creatinine was 404 μmol/L (normal, 0 to 85 μmol/L), and her platelet count was normal. On short adrenocorticotropic hormone stimulation test, baseline plasma cortisol was 123 nmol/L and the peak was 129 nmol/L. She was treated with hydrocortisone, fludrocortisone, and 0.9% saline with resolution of symptoms and normalization of electrolytes, calcium, and renal function. Computed tomography showed bilateral adrenal masses. Core needle biopsy was consistent with necrosis. There were no bleeding disorders on hematologic work 3 months later. [https://www.selleckchem.com/products/epz005687.html selleck] The most likely etiology of bilateral adrenal hemorrhage was heparin-induced thrombocytopenia from dalteparin. Conclusion This case highlights the importance of vigilance for the complication of bilateral adrenal hemorrhage with adrenal insufficiency in patients receiving dalteparin for DVT prophylaxis.Objective Hypercalcemia of malignancy (HCM) is caused by 1 of 5 known mechanisms including systemic release of ectopic parathyroid hormone (PTH)-related protein (PTHrP), calcitriol, PTH, cytokines, or destruction of bone by osteolytic metastases. We report the first case of 2 simultaneous mechanisms for HCM in a patient with a peripheral nerve sheath tumor (PNST). Methods PubMed and Google Scholar searches were performed using "hypercalcemia of malignancy" as the search term. Results A 26-year-old woman with neurofibromatosis presented with worsening left hip pain. Magnetic resonance imaging showed a large left paraspinal mass, subtotal resection of which confirmed PNST. Despite chemo-radiation therapy, the tumor progressed over 16 months, requiring tumor debulking and L3-4 lumbar laminectomy. The patient developed progressive bilateral lower extremity weakness due to direct tumor invasion of the lumbosacral vertebrae with concurrent hypercalcemia. Ionized calcium was 1.47 mmol/dL (reference range is 0.95 to sed in detail.Objective To report a massive increase in subcutaneous insulin requirements following spinal cord injury in a type 1 diabetic and how it was managed over a 22-month period with pramlintide. Methods A case report and brief literature review is presented. Results The patient is a 43-year-old male who was diagnosed with type 1 diabetes mellitus at age 18. He remained relatively well-controlled without end-organ complications until age 37, when he developed a spinal epidural abscess following a methicillin-resistant Staphylococcus aureus cellulitis of the foot. The patient became ventilator-dependent and tetraplegic. He remained in rehabilitation for 18 months and returned home with a total daily dose of subcutaneous insulin of 600 U (4 U/kg); a 500 U increase over his prespinal cord injury requirements. Total daily intravenous insulin requirement was determined to be 259 U (1.96 U/kg). The patient was started on pramlintide. Twenty-two months after the onset of pramlintide treatment his total daily dose of subcutaneous insulin was decreased to 150 U (1.3 U/kg). Conclusion Maintenance of glycemic control and obesity in type 1 diabetics with spinal cord injury may be complicated by autonomic dysregulation and the inability to induce activity-related lifestyle changes. Our patient exhibited clinical evidence of impaired subcutaneous insulin absorption that was not ameliorated by site changes, leading to massive insulin requirements which greatly reduced his quality of life. Following treatment with pramlintide, he decreased the volume of his insulin injections and lost 19 kg (41 pounds). Uncovering the precise mechanisms by which pramlintide benefited our patient requires further studies.